Dr. Reddy’s Laboratories Ltd, along with its subsidiaries, has announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the US, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Ltd, a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the US. MSN is responsible for the development and manufacturing of the product. Bosutinib Tablets (400mg) was a first-to-file product and is eligible for 180-days of generic drug exclusivity for this strength, in the U.S. The Bosulif brand (400mg) had U.S. sales of approximately $253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data.
Aurobindo Pharma USFDA inspection
The United States Food and Drug Administration (US FDA) inspected Eugia Unit-III, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of Aurobindo Pharma, situated at Phase-III, TSIIC, EPIP, IDA, Pashamylaram, Patancher, Telangana. The inspection had concluded with 11 observations. The USFDA has now determined that the inspection classification of this facility is “official action indicated” (OAI). The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe, it said.
Ipca Laboratories biologics partnership
Ipca Laboratories has inked an agreement with Mangalore-headquartered Bhami Research Laboratories for access to a biologics delivery platform to develop monoclonal antibodies. The licensing agreement grants Ipca access to BRL’s proprietary high-concentration subcutaneous biologics delivery platform for the development and commercialisation of multiple monoclonal antibody products targeting oncology and inflammatory diseases, a note from the company said.
Krishna Institute of Medical Sciences warrants issue
The Board of Krishna Institute of Medical Sciences has approved the preferential allotment of 77.02 lakh warrants worth Rs 600 crore to the promoter group. The issue price has been fixed at Rs 779 per warrant.
- Read also:
Kabra Drugs Chhattisgarh pharma facility
Kabra Drugs Ltd has received a Letter of Intent (LOI) from the Government of Chhattisgarh for the proposed establishment of a pharmaceutical manufacturing facility at Nava Raipur Pharma Park, Chhattisgarh. The proposed project envisages an investment of approximately ₹200 Crore and is expected to strengthen the Company’s manufacturing capabilities and support its long-term growth strategy. The project is expected to generate approximately 250 direct and indirect employment opportunities.
Concord Biotech ANVISA inspection
Concord Biotech Limited has announced the successful completion of an ANVISA inspection conducted by the Brazilian Health Regulatory Agency at our API manufacturing facility in Limbasi. The inspection took place from June 8 to June 12, 2026, and was concluded successfully.
Vivanta Industries Qness Pharmaceuticals partnership
In a major step toward expanding its footprints in the healthcare sector, Vivanta Industries Ltd has officially entered into business collaboration agreements with domestic player Qness Pharmaceuticals. The partnership marks a calculated effort by Vivanta to deepen its commercial presence in the manufacturing, supply, and marketing of pharmaceutical and allied products.
Suven Life Sciences SLEEP-2026 presentation
Suven Life Sciences Ltd, a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders has announced that it will present three posters at SLEEP-2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), LLC (APSS) being held at Baltimore, USA during June 14-17, 2026.